罗克韦尔医疗公司第四季度初步销售额超出预期

2026-01-20 19:32

Rockwell Medical (RMTI) expects Q4 net sales of around $18.6M, above analysts’ estimates of $16.55M, and full-year 2025 sales of ~$69.5M (vs. $67.46M estimated).
Preliminary gross margin for Q4 is estimated at ~22%, up from 14% in the third quarter of 2025. Cash flow from operations is estimated to be ~$2.3M for the quarter, which represents the second cash flow positive quarter in 2025.
As a result, cash and cash equivalents and investments available-for-sale at December 31, 2025, are expected to increase to ~$25M.
Mark Strobeck, president and CEO of Rockwell Medical, said. "We saw a considerable increase in revenue, were cash flow positive, were adjusted EBITDA positive, and we improved our cash position. Additionally, we continued to improve on our operational efficiencies and reduce expenses, which resulted in a gross margin of 22% in Q4, representing a notable improvement over every quarter in 2025. As we look to 2026, we are focused on three main areas: revenue growth, increased profitability, and portfolio diversification."
RMTI +31.6% premarket to $1.26
Source: Press Release

More on Rockwell Medical